Need help finding what you are looking for?
Contact Us
PUBLISHER: KBV Research | PRODUCT CODE: 1292759
PUBLISHER: KBV Research | PRODUCT CODE: 1292759
LAMEA Musculoskeletal Disorders Drugs Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration, By Drug Type, By Country and Growth Forecast, 2023 - 2029
PUBLISHED:
PAGES: 102 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The Latin America, Middle East and Africa Musculoskeletal Disorders Drugs Market would witness market growth of 10.2% CAGR during the forecast period (2023-2029).
There are currently several novel medications in the process of being developed, and these drugs show promise of being safer and more efficient than the already available treatments. In the years to come, the expansion of the pharmaceutical industry for treating musculoskeletal disorders is likely driven by the introduction of these new drugs. One of the most important chances for the expansion of the market is presented by the growing quantity of clinical tests performed to discover new medications. In addition, the growing number of approvals for the application of biologics would also boost the market's development.
In musculoskeletal drug delivery, the term "drug" is not restricted to therapeutic agents like anti-inflammatory drugs, antibiotics, and anti-cancer agents; its scope has expanded dramatically over the past few decades to embrace growth factors, non-viral genes (DNAs, RNAs), as well as tissue engineering scaffolds and regenerative cells/tissues. Non-steroidal anti-inflammatory drugs (NSAIDs), antimicrobial & antiviral drugs, and anti-cancer drugs are the three broad categories that categorize conventional medications. NSAIDs are one of the most commonly used drugs to reduce inflammation by inhibiting cyclooxygenases, predominantly for osteoarthritis and other chronic musculoskeletal conditions.
Israel's population is aging faster than the global average, as is the case in many other countries. The percentage of adults 65 and older has increased by 18 since 1950. The overall population of Israel is expected to reach 12.1 million by 2035, with seniors making up roughly 14% of the total, or 1.9 million people. When Israel was established in 1948, only 4% of the populace was over 65. Over time, this population has steadily grown. Since 1995, the average rise in life expectancy has been 1%, and this trend is anticipated to continue. In addition, as musculoskeletal diseases are more common among the elderly, the demand for drugs to treat these illnesses is predicted to rise, propelling market expansion in LAMEA.
The Brazil market dominated the LAMEA Musculoskeletal Disorders Drugs Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $2,387.4 Million by 2029. The Argentina market is showcasing a CAGR of 10.8% during (2023 - 2029). Additionally, The UAE market would register a CAGR of 9.9% during (2023 - 2029).
Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on Drug Type, the market is segmented into Analgesics, DMARDs, Corticosteroids and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Amgen, Inc., Eli Lilly And Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and UCB S.A.
Scope of the Study
Market Segments covered in the Report:
By Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Route of Administration
- Parenteral
- Oral
By Drug Type
- Analgesics
- DMARDs
- Corticosteroids
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- AbbVie, Inc.
- Amgen, Inc.
- Eli Lilly And Company
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
- UCB S.A.
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 LAMEA Musculoskeletal Disorders Drugs Market, by Distribution Channel
- 1.4.2 LAMEA Musculoskeletal Disorders Drugs Market, by Route of Administration
- 1.4.3 LAMEA Musculoskeletal Disorders Drugs Market, by Drug Type
- 1.4.4 LAMEA Musculoskeletal Disorders Drugs Market, by Country
- 1.5 Methodology for the research
Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market composition & scenario
- 2.1.1 Overview
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
- 3.1 KBV Cardinal Matrix
- 3.2 Recent Industry Wide Strategic Developments
- 3.2.1 Partnerships, Collaborations and Agreements
- 3.2.2 Geographical Expansions
- 3.2.3 Acquisition and Mergers
- 3.2.4 Approvals and Trials
- 3.3 Top Winning Strategies
- 3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. LAMEA Musculoskeletal Disorders Drugs Market by Distribution Channel
- 4.1 LAMEA Drug Stores & Retail Pharmacies Market by Country
- 4.2 LAMEA Hospital Pharmacies Market by Country
- 4.3 LAMEA Online Providers Market by Country
Chapter 5. LAMEA Musculoskeletal Disorders Drugs Market by Route of Administration
- 5.1 LAMEA Parenteral Market by Country
- 5.2 LAMEA Oral Market by Country
Chapter 6. LAMEA Musculoskeletal Disorders Drugs Market by Drug Type
- 6.1 LAMEA Analgesics Market by Country
- 6.2 LAMEA DMARDs Market by Country
- 6.3 LAMEA Corticosteroids Market by Country
- 6.4 LAMEA Others Market by Country
Chapter 7. LAMEA Musculoskeletal Disorders Drugs Market by Country
- 7.1 Brazil Musculoskeletal Disorders Drugs Market
- 7.1.1 Brazil Musculoskeletal Disorders Drugs Market by Distribution Channel
- 7.1.2 Brazil Musculoskeletal Disorders Drugs Market by Route of Administration
- 7.1.3 Brazil Musculoskeletal Disorders Drugs Market by Drug Type
- 7.2 Argentina Musculoskeletal Disorders Drugs Market
- 7.2.1 Argentina Musculoskeletal Disorders Drugs Market by Distribution Channel
- 7.2.2 Argentina Musculoskeletal Disorders Drugs Market by Route of Administration
- 7.2.3 Argentina Musculoskeletal Disorders Drugs Market by Drug Type
- 7.3 UAE Musculoskeletal Disorders Drugs Market
- 7.3.1 UAE Musculoskeletal Disorders Drugs Market by Distribution Channel
- 7.3.2 UAE Musculoskeletal Disorders Drugs Market by Route of Administration
- 7.3.3 UAE Musculoskeletal Disorders Drugs Market by Drug Type
- 7.4 Saudi Arabia Musculoskeletal Disorders Drugs Market
- 7.4.1 Saudi Arabia Musculoskeletal Disorders Drugs Market by Distribution Channel
- 7.4.2 Saudi Arabia Musculoskeletal Disorders Drugs Market by Route of Administration
- 7.4.3 Saudi Arabia Musculoskeletal Disorders Drugs Market by Drug Type
- 7.5 South Africa Musculoskeletal Disorders Drugs Market
- 7.5.1 South Africa Musculoskeletal Disorders Drugs Market by Distribution Channel
- 7.5.2 South Africa Musculoskeletal Disorders Drugs Market by Route of Administration
- 7.5.3 South Africa Musculoskeletal Disorders Drugs Market by Drug Type
- 7.6 Nigeria Musculoskeletal Disorders Drugs Market
- 7.6.1 Nigeria Musculoskeletal Disorders Drugs Market by Distribution Channel
- 7.6.2 Nigeria Musculoskeletal Disorders Drugs Market by Route of Administration
- 7.6.3 Nigeria Musculoskeletal Disorders Drugs Market by Drug Type
- 7.7 Rest of LAMEA Musculoskeletal Disorders Drugs Market
- 7.7.1 Rest of LAMEA Musculoskeletal Disorders Drugs Market by Distribution Channel
- 7.7.2 Rest of LAMEA Musculoskeletal Disorders Drugs Market by Route of Administration
- 7.7.3 Rest of LAMEA Musculoskeletal Disorders Drugs Market by Drug Type
Chapter 8. Company Profiles
- 8.1 Johnson & Johnson
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Segmental &Regional Analysis
- 8.1.4 Research & Development Expenses
- 8.1.5 Recent strategies and developments:
- 8.1.5.1 Partnerships, Collaborations, and Agreements:
- 8.1.6 SWOT Analysis
- 8.2 Pfizer, Inc.
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Regional & Segmental Analysis
- 8.2.4 Research & Development Expense
- 8.2.5 Recent strategies and developments:
- 8.2.5.1 Partnerships, Collaborations, and Agreements:
- 8.2.5.2 Acquisition and Mergers:
- 8.3 AbbVie, Inc.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Regional Analysis
- 8.3.4 Research & Development Expense
- 8.3.5 Recent strategies and developments:
- 8.3.5.1 Approvals and Trials:
- 8.3.5.2 Acquisition and Mergers:
- 8.3.5.3 Geographical Expansions:
- 8.4 UCB S.A.
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Regional Analysis
- 8.4.4 Research & Development Expense
- 8.4.5 Recent strategies and developments:
- 8.4.5.1 Partnerships, Collaborations, and Agreements:
- 8.4.5.2 Acquisition and Mergers:
- 8.5 Amgen, Inc.
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Regional Analysis
- 8.5.4 Research & Development Expenses
- 8.5.5 Recent strategies and developments:
- 8.5.5.1 Acquisition and Mergers:
- 8.6 Eli Lilly And Company
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Regional Analysis
- 8.6.4 Research & Development Expenses
- 8.7 F. Hoffmann-La Roche Ltd.
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Segmental and Regional Analysis
- 8.7.4 Research & Development Expense
- 8.8 Merck & Co., Inc.
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Segmental and Regional Analysis
- 8.8.4 Research & Development Expenses
- 8.9 Novartis AG
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Segmental and Regional Analysis
- 8.9.4 Research & Development Expense
- 8.10. Teva Pharmaceutical Industries Ltd.
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Regional Analysis
- 8.10.4 Research & Development Expenses
LIST OF TABLES
- TABLE 1 LAMEA Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
- TABLE 2 LAMEA Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
- TABLE 3 Partnerships, Collaborations and Agreements- Musculoskeletal Disorders Drugs Market
- TABLE 4 geographical expansions - Musculoskeletal Disorders Drugs Market
- TABLE 5 Acquisition and Mergers- Musculoskeletal Disorders Drugs Market
- TABLE 6 Approvals and trials - Musculoskeletal Disorders Drugs Market
- TABLE 7 LAMEA Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 8 LAMEA Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 9 LAMEA Drug Stores & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
- TABLE 10 LAMEA Drug Stores & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
- TABLE 11 LAMEA Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
- TABLE 12 LAMEA Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
- TABLE 13 LAMEA Online Providers Market by Country, 2019 - 2022, USD Million
- TABLE 14 LAMEA Online Providers Market by Country, 2023 - 2029, USD Million
- TABLE 15 LAMEA Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
- TABLE 16 LAMEA Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
- TABLE 17 LAMEA Parenteral Market by Country, 2019 - 2022, USD Million
- TABLE 18 LAMEA Parenteral Market by Country, 2023 - 2029, USD Million
- TABLE 19 LAMEA Oral Market by Country, 2019 - 2022, USD Million
- TABLE 20 LAMEA Oral Market by Country, 2023 - 2029, USD Million
- TABLE 21 LAMEA Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
- TABLE 22 LAMEA Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
- TABLE 23 LAMEA Analgesics Market by Country, 2019 - 2022, USD Million
- TABLE 24 LAMEA Analgesics Market by Country, 2023 - 2029, USD Million
- TABLE 25 LAMEA DMARDs Market by Country, 2019 - 2022, USD Million
- TABLE 26 LAMEA DMARDs Market by Country, 2023 - 2029, USD Million
- TABLE 27 LAMEA Corticosteroids Market by Country, 2019 - 2022, USD Million
- TABLE 28 LAMEA Corticosteroids Market by Country, 2023 - 2029, USD Million
- TABLE 29 LAMEA Others Market by Country, 2019 - 2022, USD Million
- TABLE 30 LAMEA Others Market by Country, 2023 - 2029, USD Million
- TABLE 31 LAMEA Musculoskeletal Disorders Drugs Market by Country, 2019 - 2022, USD Million
- TABLE 32 LAMEA Musculoskeletal Disorders Drugs Market by Country, 2023 - 2029, USD Million
- TABLE 33 Brazil Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
- TABLE 34 Brazil Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
- TABLE 35 Brazil Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 36 Brazil Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 37 Brazil Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
- TABLE 38 Brazil Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
- TABLE 39 Brazil Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
- TABLE 40 Brazil Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
- TABLE 41 Argentina Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
- TABLE 42 Argentina Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
- TABLE 43 Argentina Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 44 Argentina Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 45 Argentina Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
- TABLE 46 Argentina Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
- TABLE 47 Argentina Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
- TABLE 48 Argentina Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
- TABLE 49 UAE Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
- TABLE 50 UAE Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
- TABLE 51 UAE Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 52 UAE Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 53 UAE Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
- TABLE 54 UAE Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
- TABLE 55 UAE Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
- TABLE 56 UAE Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
- TABLE 57 Saudi Arabia Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
- TABLE 58 Saudi Arabia Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
- TABLE 59 Saudi Arabia Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 60 Saudi Arabia Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 61 Saudi Arabia Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
- TABLE 62 Saudi Arabia Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
- TABLE 63 Saudi Arabia Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
- TABLE 64 Saudi Arabia Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
- TABLE 65 South Africa Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
- TABLE 66 South Africa Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
- TABLE 67 South Africa Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 68 South Africa Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 69 South Africa Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
- TABLE 70 South Africa Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
- TABLE 71 South Africa Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
- TABLE 72 South Africa Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
- TABLE 73 Nigeria Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
- TABLE 74 Nigeria Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
- TABLE 75 Nigeria Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 76 Nigeria Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 77 Nigeria Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
- TABLE 78 Nigeria Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
- TABLE 79 Nigeria Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
- TABLE 80 Nigeria Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
- TABLE 81 Rest of LAMEA Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
- TABLE 82 Rest of LAMEA Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
- TABLE 83 Rest of LAMEA Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 84 Rest of LAMEA Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 85 Rest of LAMEA Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
- TABLE 86 Rest of LAMEA Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
- TABLE 87 Rest of LAMEA Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
- TABLE 88 Rest of LAMEA Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
- TABLE 89 Key information -Johnson & Johnson
- TABLE 90 Key Information - Pfizer, Inc.
- TABLE 91 Key information - AbbVie, Inc.
- TABLE 92 Key Information - UCB S.A.
- TABLE 93 Key Information - Amgen, Inc.
- TABLE 94 Key Information - Eli Lilly And Company
- TABLE 95 KEY INFORMATION - F. Hoffmann-La Roche Ltd.
- TABLE 96 KEY INFORMATION - Merck & Co., Inc.
- TABLE 97 Key Information - Novartis AG
- TABLE 98 Key Information - Teva Pharmaceuticals Industries Ltd.
List of Figures
- FIG 1 Methodology for the research
- FIG 2 KBV Cardinal Matrix
- FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
- FIG 4 LAMEA Musculoskeletal Disorders Drugs Market Share by Distribution Channel, 2022
- FIG 5 LAMEA Musculoskeletal Disorders Drugs Market Share by Distribution Channel, 2029
- FIG 6 LAMEA Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2029, USD Million
- FIG 7 LAMEA Musculoskeletal Disorders Drugs Market Share by Route of Administration, 2022
- FIG 8 LAMEA Musculoskeletal Disorders Drugs Market Share by Route of Administration, 2029
- FIG 9 LAMEA Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2029, USD Million
- FIG 10 LAMEA Musculoskeletal Disorders Drugs Market Share by Drug Type, 2022
- FIG 11 LAMEA Musculoskeletal Disorders Drugs Market Share by Drug Type, 2029
- FIG 12 LAMEA Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2029, USD Million
- FIG 13 LAMEA Musculoskeletal Disorders Drugs Market Share by Country, 2022
- FIG 14 LAMEA Musculoskeletal Disorders Drugs Market Share by Country, 2029
- FIG 15 LAMEA Musculoskeletal Disorders Drugs Market by Country, 2019 - 2029, USD Million
- FIG 16 SWOT analysis: Johnson & Johnson
- FIG 17 Recent strategies and developments: Pfizer, Inc.
- FIG 18 Recent strategies and developments: AbbVie, Inc.
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.